Traditional and New Composite Endpoints in Heart Failure Clinical Trials: Facilitating Comprehensive Efficacy Assessments and Improving Trial Efficiency
Year: 2016
Type: review
Abstract: Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of patients to accrue a sufficient number of outcome events and have adequate power to draw conclusions about the efficacy and safety of new treatments for heart failure. Additionally, the societal and health system perspectives on heart failure have raised interest in ascertaining the effects of therapy on outcomes such as repeat hospitalization and the patient's burden of disease. Thus, novel methods for using composite endpoints in clinical trials (e.g. clinical status composite endpoints, recurrent event analyses) are being applied in current and planned trials. Endpoints that measure functional status or reflect the patient experience are important but used cautiously because heart failure treatments may improve function yet have adverse effects on mortality. This paper discusses the use of traditional and new composite endpoints, identifies qualities of robust composites, and outlines opportunities for future research.
DOI: 10.1002/ejhf.516
Authors: Stefan D. Anker, Stefan Schroeder, Dan Atar, Jeroen J. Bax, Claudio Ceconi, Martin R. Cowie, Adam Crisp, Fabienne Dominjon, Ian Ford, Hossein-Ardeschir Ghofrani, Savion Gropper, Gerhard Hindricks, Mark A. Hlatky, Richard Holcomb, Narimon Honarpour, J. Wouter Jukema, Albert M. Kim, Michael Kunz, Martin Lefkowitz, Chantal Le Floch, Ulf Landmesser, Theresa A. McDonagh, John J. McMurray, Bela Merkely, Milton Packer, Krishna Prasad, James Revkin, Giuseppe M.C. Rosano, Ransi Somaratne, Wendy Gattis Stough, Adriaan A. Voors, Frank Ruschitzka
Institutions: Universitätsmedizin Göttingen, Bayer (Germany), Oslo University Hospital, University of Oslo, Leiden University Medical Center, Azienda Socio Sanitaria Territoriale del Garda, Imperial College London, GlaxoSmithKline (United Kingdom), University of Glasgow, Justus-Liebig-Universität Gießen, German Center for Lung Research, Universities of Giessen and Marburg Lung Center, Kerckhoff Klinik, Boehringer Ingelheim (Germany), Leipzig University, Stanford Medicine, Stanford University, Amgen (United States), Pfizer (United States), Novartis (United States), Charité – Universitätsmedizin Berlin, King's College Hospital, Semmelweis University, The University of Texas Southwestern Medical Center, Medicines and Healthcare products Regulatory Agency, St George's, University of London, Istituti di Ricovero e Cura a Carattere Scientifico, IRCCS San Raffaele Roma, Campbell University, University of Groningen, University of Zurich
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: European Society of Cardiology
OpenAlex ID: W2339635573
